FiercePharma1d
Merck KGaA’s EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad
Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...
pharmaphorum2d
BMS gets FDA nod for ozanimod, but launch will be delayed
There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...
pharmaphorum2d
Roche's MS drug Ocrevus priced in line with Novartis rival in UK
Merck KGaA's recently approved MS pill Mavenclad (cladribine) is also available to NHS patients after the company agreed to only charge for patients that respond to the treatment. Biogen has ...
Multiple Sclerosis Market Size to Hit USD 43.40 Billion by 2032, Growing at a CAGR of 7.00% - SNS Insider
Multiple Sclerosis Market Growth is Driven by Advanced Treatment Solutions and Rising Patient PopulationsPune, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Multiple Sclerosis Market Size & Growth Analysis: ...